medigraphic.com
ISSN 1527-3172 (Electronic)

2014, Number 3-4

<< Back Next >>

MEDICC Review 2014; 16 (3-4)

Antenatal testing for cystic fibrosis in Cuba, 1988−2011

Collazo MT, López RI, Clark FY, Piloto RY, González BL, Gómez MM, García HM, Reyes NL, Rodríguez CF

Language: English
References: 31
Page: 18-21
PDF size: 132.79 Kb.


ABSTRACT

Introduction: Cystic fibrosis is a multisystem autosomal recessive disease with wide variability in clinical severity. It is incurable and characterized by elevated and premature mortality, as well as poor quality of life. Its frequency, lethality and devastating impact on both the physical and psychological wellbeing of patients and their families, make it a serious health problem. Its frequency in Cuba is 1 in 9862 live births, where marked molecular heterogeneity of the CFTR gene makes molecular diagnosis difficult. Six mutations have been identified that together enable molecular characterization of only 55.5% of cystic fibrosis chromosomes. This paper presents national results of antenatal diagnostic testing, using direct and indirect methods, for detection of cystic fibrosis.
Objetives: Characterize the Cuban public health system's experience with antenatal molecular testing for cystic fibrosis from 1988 through 2011.
Methods: A retrospective descriptive study was conducted with results of antenatal diagnostic testing of amniotic fluid, performed nationwide from 1988 through 2011, for 108 fetuses of couples with some risk of having children affected by cystic fibrosis, who requested testing. Polymerase chain reaction detected mutations p.F508del, p.G542X, p.R1162X, p.R334W, p.R553X and c.3120+1G › A, and markers XV2C and KM19. Data were analyzed using absolute frequencies and percentages, and presented in tables.
Results: For 93 cases (86.1%), testing for cystic fibrosis was done using direct analysis of mutations p.F508del, p.G542X, p.R1162X, p.R334W, p.R553X and c.3120+1G › A; five cases (4.6%) were tested indirectly using markers XV2C/Taq I and KM19/Pst I; and 10 (9.3%) were tested using a combination of the two methods. A total of 72 diagnoses (66.7% of studies done) were concluded, of which there were 20 healthy fetuses, 16 affected, 27 carrier, and 9 who were either healthy or carriers of an unknown mutation.
Conclusions: Direct or indirect molecular study was successfully used in over half of antenatal tests requested by couples throughout Cuba at risk of having children affected by cystic fibrosis, which is of great social value because of CF's burden on affected persons and their families.


REFERENCES

  1. El-Seedy A, Girodon E, Norez C, Pajaud J, Pasquet MC, de Becdelièvre A, et al. CFTR mutation combinations producing frequent complex alleles with different clinical and functional outcomes. Hum Mutat. 2012 Nov;33(11):1557–65.

  2. Dickinson F, Batlle M, Razón R, Ramos L, Pérez M. Caracterización epidemiológica de pacientes pediátricos con fibrosis quística. Rev Cubana Pediatr [Internet]. 2005 Apr–Jun [cited 2012 Oct 6];77(2):[about 6 p.]. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0034-75312005000200001&nrm=iso. Spanish.

  3. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med. 2005 May 12;352(19):1992–2001.

  4. Castellani C, Cuppens H, Macek M Jr, Cassiman JJ, Kerem E, Durie P, et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros. 2008 May;7(3):179–96.

  5. Casals T. Epidemiología y patogénesis. In: Manual de Fibrosis Quística. Barcelona: Sociedad científica de lucha contra la fibrosis quística; 2003. p. 13–9. Spanish.

  6. Cystic fibrosis. A WHO/ICF(M)A meeting. Bull World Health Organ. 1985;63(1):1–10.

  7. Collazo T. Estudio molecular de la fibrosis quística en Cuba [thesis]. [Havana]: University of Medical Sciences of Havana (CU); 2006. Spanish.

  8. Razón R, Rodríguez F, Rojo M, González J, Abreu G, Pérez T, et al. La fibrosis quística en Cuba. Rev Cubana Pediatr. 2009;81(Suppl):S85–92. Spanish.

  9. Kerem B, Rommens JM, Buchanan JA, Markiewicz DA, Cox TK, Chakravarti A, et al. Identification of the cystic fibrosis gene: genetic analysis. Science. 1989 Sep 8;245(4922):1073–80.

  10. Cystic Fibrosis mutation database [Internet]. Toronto: Cystic Fibrosis Centre at the hospital for sick children in Toronto. c2010. CFMDB Statistics; [updated 2011 Apr 25; cited 2014 Jan 14]; [about 2 p.]. Available from: http://www.genet.sickkids.on.ca/StatisticsPage.html

  11. Alonso MJ, Heine-Suñer D, Calvo M, Rosell J, Giménez J, Ramos MD, et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. Ann Hum Genet. 2007 Mar;71(Pt 2):194–201.

  12. Ivady G, Madar L, Nagy B, Gonczi F, Ajzner E, Dzsudzsak E, et al. Distribution of CFTR mutations in Eastern Hungarians: relevance to genetic testing and to the introduction of newborn screening for cystic fibrosis. J Cyst Fibros. 2011 May;10(3):217–20.

  13. Bieger AM, Marson FA, Bertuzzo CS. Prevalence of ΔF508 mutation in the cystic fibrosis transmembrane conductance regulator gene among cystic fibrosis patients from a Brazilian referral center. J Pediatr (Rio J). 2012 Nov–Dec;88(6):531–4.

  14. Teruel BM, Rodríguez JJ, McKeigue P, Mesa TC, Fuentes E, Cepero AV, et al. Interactions between genetic admixture, ethnic identity, APOE genotype and dementia prevalence in an admixed Cuban sample; a cross-sectional population survey and nested case-control study. BMC Med Genet. 2011 Mar 24;12:43.

  15. Collazo T, Bofill AM, Clark Y, Hernández Y, Gómez M, Rodríguez F, et al. Common mutations in Cuban cystic fibrosis patients. J Cyst Fibros. 2009 Jan;8(1):47–9.

  16. Boúe A, Muller F, Nezelof C, Oury JF, Duchatel F, Dumez Y, et al. Prenatal Diagnosis in 200 pregnancies with ¼ risk of cystic fibrosis. Hum Gen. 1986 Nov;74(3):288–97.

  17. Casals T, Nunes V, Lázaro C, Jiménez J, Girbau E, Volpini V, et al. Mutation and linkage disequilibrium analysis in genetic counselling of Spanish cystic fibrosis families. J Med Genet. 1991 Nov;28(11):771–6.

  18. Baranov VS, Gorbunova VM, Ivaschenko TE, Shwed NYu, Osinovskaya NS, Kascheeva TK, et al. Five years' experience of prenatal diagnosis of cystic fibrosis in the former U.S.S.R. Prenat Diagn. 1992 Jul;12(7):575–86.

  19. Miller SA. A simple salting out procedure for extracting DNA from human nucleoted cells. Nucleic Acids Res. 1988 Feb 11;16(3):1215.

  20. Casals T, Nuñez V, Giménez J, Parra J, Estivill X. Diagnóstico prenatal de fibrosis quística en familias españolas utilizando marcadores del DNA: nuestra experiencia en 1987-1989. An Esp Pediatric. 1990 Apr;32(4):287–92. Spanish.

  21. Newton CR, Graham A, Heptinstall LE, Powell SJ, Summers C, Kalsheker N, et al. Analysis any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res. 1989 Apr 11;17(7):2503–16.

  22. Gasparini P, Borgo G, Mastella G, Bonizzato A, Dognini M, Pignatti PF. Nine cystic fibrosis patients homozygous for the CFTR nonsense mutation R1162X have mild or moderate lung disease. J Med Genet. 1992 Aug;29(8):558–62.

  23. Cutting GR, Kash LM, Rosenstein BJ, Zielenski J, Tsui LC, Antonarakis SE, et al. A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature. 1990 Jul 26;346(6282):366–9.

  24. Zielenski J, Rozmahel R, Bozon D, Kerem B, Grzelczak Z, Riordan JR, et al. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics. 1991 May;10:214–28.

  25. Pérez MM, Luna MC, Pivetta OH, Keyeux G. CFTR gene analysis in Latin American CF patients: heterogeneous origin and distribution of mutations across the continent. J Cyst Fibros. 2007 May;6(3):194–208.

  26. Ustáriz CR, Morera LM, Hernández P, Estrada M, Bencomo A, García MA, et al. Origen y composición genética de la población cubana. Rev Cubana Hematol Inmunol Hemoter [Internet]. 2011 [cited 2013 Jun 11];27(3):[about 4 p.]. Available from: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892011000300002&lng=es. Spanish.

  27. Chávez M, García RJ, Vigueras RM, Orozco L. Diagnóstico prenatal en una familia con fibrosis quística: combinación de estrategias moleculares para un diagnóstico preciso. Rev Invest Clin. 2011 Jul–Aug;63(4):433–5. Spanish.

  28. World Health Organization. The molecular genetic epidemiology of cystic fibrosis. Report of a joint meeting of WHO/ECFTN/ICF(M)A/ECFS. Geneva: World Health Organization; 2004.

  29. Elce A, Boccia A, Cardillo G, Giordano S, Tomaiuolo R, Paolella G, et al. Three novel CFTR polymorphic repeats improve segregation analysis for cystic fibrosis. Clin Chem. 2009 Jul;55(7):1372–9.

  30. González L, Collazo T, Clark Y, Gómez M, Reyes L. Caracterización del marcador microsatélite IVS17bTA y seis mutaciones del gen CFTR en 21 familias cubanas con fibrosis quística. Biotecnol Apl. 2013 Oct–Dec;30(4):262–6. Spanish.

  31. Tomaiuolo R, Nardiello P, Martinelli P, Sacchetti L, Salvatore F, Castaldo G. Prenatal diagnosis of cystic fibrosis: an experience of 181 cases. Clin Chem Lab Med. 2013 Dec;51(12):2227–32.




2020     |     www.medigraphic.com